Oxford BioDynamics (LON:OBD) Stock Price Down 2.2% – What’s Next?

Oxford BioDynamics Plc (LON:OBD)’s share price traded down 2.2% during trading on Wednesday . The stock traded as low as GBX 0.21 and last traded at GBX 0.22. 591,363 shares changed hands during trading, a decline of 98% from the average session volume of 28,292,693 shares. The stock had previously closed at GBX 0.23.

Analyst Upgrades and Downgrades

Separately, Shore Capital reaffirmed a “house stock” rating on shares of Oxford BioDynamics in a research note on Wednesday, October 8th.

Oxford BioDynamics Price Performance

The company’s 50 day simple moving average is GBX 0.27 and its 200 day simple moving average is GBX 0.39. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80. The stock has a market cap of £8.71 million, a P/E ratio of -0.07 and a beta of 0.42.

Oxford BioDynamics (LON:OBD) last announced its quarterly earnings results on Wednesday, December 24th. The biotechnology company reported GBX (0.80) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.